Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
Authors:
Open Access
- 2 July 2015
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 106 (8) , 945-950
Abstract
Recent progress in tumor immunology has revealed that tumors generate immunologically restrained milieu during the process of their growth, which facilitates the escape of tumors from host immune systems. Immune checkpoint molecules, which transduce co‐inhibitory signals to immuno‐competent cells, are one of the most important components conferring the immunosuppressive capacity in the tumor microenvironment. Cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) and programmed cell death‐1 (PD‐1) are typical immune checkpoint molecules intimately involved in the suppression of anti‐tumor immunity. Antibodies against those molecules have been developed, such as ipilimumab (anti‐CTLA‐4 antibody), nivolumab and pembrolizumab (anti‐PD‐1 antibody), and have been approved by regulatory agencies and used in some countries. Treatment with these antibodies demonstrates previously unobserved clinical efficacies superior to the conventional therapies. In this review, we first discuss the escape mechanisms of cancer from host immune systems, and then focus on the recent advances in immune checkpoint blockade therapy and on the new findings of related immune reactions, aiming to provide a better understanding of the novel cancer immunotherapies.Keywords
This publication has 55 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Cancer Immunotherapy Comes of AgeJournal of Clinical Oncology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends in Immunology, 2010
- CTLA-4: a key protein in autoimmunityNature Reviews Rheumatology, 2009
- About human tumor antigens to be used in immunotherapySeminars in Immunology, 2008
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002